awmsg logo



cetuximab (Erbitux®)


Reference No. 81

Publication date:
15/06/2006


Appraisal information

cetuximab (Erbitux®) 5 mg/ml solution for infusion


Company: Merck Serono Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: 02/03/2006
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: Not available
Ministerial ratification: 14/06/2006

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA118) NICE GUIDANCE ISSUED JANUARY 2007 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) The use of cetuximab (Erbitux®), in combination with irinotecan, should be endorsed within NHS Wales, with specific restrictions applied, for the treatment of EGFR-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. Treatment must only be initiated and administered under the supervision of a physician experienced in the use of chemotherapeutic agents.
Final Appraisal Recommendation (FAR)
Download